Quantum BioPharma (NASDAQ: QNTM | CSE: QNTM) is a clinical-stage biotech advancing a breakthrough treatment for multiple sclerosis. Its lead drug, Lucid-MS, is designed to protect and restore myelin without suppressing the immune system, a first in class approach. With a successful Phase 1 trial, a clean 90-day safety study, and regulatory submissions underway in both the U.S. and U.K., Quantum is rapidly advancing toward Phase 2 and aiming to reshape care for millions living with MS worldwide.